BlueSCAI™: Harness the Power of Ultra-Sensitive Protein Profiling in Multiplex
Unlock Critical Protein Biomarkers with Unprecedented Detection and Quantitation with Best-In-Class Platform.
BlueSCAI™
BlueSCAI:​​ (Background Lowering Using Serial Capture, Adapter Insertion)
Provides unparalleled technical performance in precision, scalable, multiplex protein profiling, incorporating a proprietary capture, release, re-capture mechanism that dramatically lowers background:
-
with down to attomolar sensitivity;
-
up to 5 logs LOD advantage over leading multiplex proteomics platform in head to head comparisons;
-
up to 1,000 fold LOD advantage over commercial ELISA’s using the same antibody pairs;
PTM’s -- detect and quantitate post-translational modification isoforms -- which leading multiplex proteomics platforms do not.
See what you are missing -- avoid the high percentage of non-detects seen with leading multiplex proteomics platforms on your biologically important, lower abundance biomarkers.
Locked-in specificity -- BlueSCAI is based on paired-antibody proximity detection for each target, in multiplex, with NGS read-out of the ligated conjugated DNA barcodes--ensuring high specificity.
Broad dynamic range -- measure changes across the biological spectrum. Tunable for optimal NGS read-out.
Profile biofluid samples, as well as cell and tissue lysates, with reaction volumes of <5uL.
No dedicated instrument required, providing maximum flexibility and ease of use. Read-out by NGS, or qPCR.
​
Technology
Multiplex Biomarker Quantification
​
ActivSignal’s BlueSCAI is built on our patented Multiplex Paired-Antibody Amplified Detection (MPAD) technology and is a highly specific and sensitive platform for profiling proteins and their modifications in multiplex.
BlueSCAI detects the protein targets using specific, dual-binding of antibody-pairs, architecture that increases specificity, an integrated capture-release-recapture mechanism that dramatically lowers background, signal amplification, and specific NGS read-out--with a large and tunable dynamic range. Highly scalable -- from single to tens to thousands of biomarkers, which can be measured in multiplex from the same small sample with high specificity and sensitivity.
​
​
​​
​
​
Approach
Earlier Detection of Pancreatic Cancer
​​
The PanDx™ assay read-out from the patient sample, across the multiple proteins and other biomarkers in the Panel, provides a “bio-signature” for that individual.
AI is then harnessed to match this bio-signature against the signatures of early-stage cancer and other related conditions, generating a diagnosis.
The combination of high specificity and sensitivity, applied to biologically important biomarkers, even those in lower abundance, and in multiplex, enables the detection of cancer at an earlier stage.
In our most recent study (n=203), on stage I and II PDAC vs. matched non-cancer controls, sensitivity was 78% at 99% specificity, with an AUC of 93% vs. 84% for CA19-9 alone.
Recognition
ActivSignal's work has been supported by multiple grant awards from the National Science Foundation and the MassVentures START program.
Company & Team
ActivSignal develops innovative, ultra-high sensitivity, multiplex protein profiling technology. In addition, the company leverages these innovations to improve cancer outcomes by detecting cancer earlier, including development of an early detection assay for pancreatic cancer.
Our team is comprised of experienced scientists dedicated to advancing ultra-sensitive proteomics, cancer diagnostics and improving patient outcomes.
